This study is currently not recruiting participants.

A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MONGERSEN (GED-0301) FOR THE TREATMENT OF SUBJECTS WITH ACTIVE CROHN'S DISEASE

Study of an Investigational Medication for Crohn's Disease

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to test the effects of an investigational study medication, GED-0301, in order to find out if GED-0301 can or cannot improve the symptoms of Crohn's disease.

Detailed description of study

The purpose of this study is to test the effects of an investigational study medication, GED-0301, in order to find out if GED-0301 can or cannot improve the symptoms of Crohn's disease.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Crohn's disease
  • Age: 100 years or below
  • Gender: All

This study investigates an investigational medication to see if it can improve the symptoms of Crohn's disease. Crohn's disease is a chronic inflammatory condition that affects the digestive tract, causing symptoms like abdominal pain and diarrhea.

Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.

  • Who can participate: Eligibility criteria will be provided by the study coordinators upon request.
  • Study details: Participants will receive either the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1512032235

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team